Tony Charara

Mable

National Finalist in EY Entrepreneur Of The Year 2025 Australia

In 2013, Tony Charara co-founded Mable Technologies with Peter Scutt. This leading health-tech platform connects individuals seeking health and support services with independent providers through a safeguarded two-sided marketplace. The Mable Group now processes over $1 billion in healthcare funds and delivers 600,000 hours of support monthly across the aged care and disability sectors in Australia.

Building on their aged care learnings, Tony and Peter established HomeMade in 2022. HomeMade is a self-managed aged care provider that leverages technology to help consumers manage their Home Care Packages. It now oversees over $100 million in healthcare funds for over 3,000 customers.

In 2014, Tony co-founded Tissue Repair Limited, where he serves as CEO. This biotechnology company will begin global phase III trials in October 2024 for its drug candidate TR-987. This innovative treatment, which stimulates the body's tissue repair pathways, aims to accelerate wound healing by 30 per cent. TR-987 is undergoing FDA approval and, if successful, will be the first new drug for chronic wounds in 25 years. Tissue Repair recently achieved TGA status for its product TR Pro+, designed to enhance skin healing and reduce recovery time following aesthetic and medical procedures.

Tony's work at Mable and Tissue Repair is driven by a commitment to using technology to solve complex problems and deliver significant social impact. This commitment has been recognised with Tony and Peter being named among the top 100 innovators by The Australian in 2022 and featured in Deloitte's Technology Fast 50 lists from 2018 to 2022. Mable was named in the AFR’s Fast 100 2021. And in 2022, Mable received a Good Design Award for its Last Minute feature, developed during the COVID-19 pandemic, to provide immediate support to clients in need during a rapidly evolving health crisis.